Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.64 |
| ▸ | PTPRF | P10586 | 1/20 | 0.64 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.64 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22628164 | 0.94 | HTT (0.71) | CYP1A2MEN1CYP3A4CYP2C9CYP2C19 | |
| N-Benzylaniline SCHEMBL7840 | 0.94 | HTT (0.71) | CYP1A2MEN1CYP3A4CYP2C9CYP2C19 | |
| N-Benzylaniline SCHEMBL2176624 | 0.92 | HTT (0.68) | CYP1A2MEN1CYP3A4CYP2C9CYP2C19 | |
| N-Benzylaniline SCHEMBL357137 | 0.92 | HTT (0.68) | CYP1A2MEN1CYP3A4CYP2C9CYP2C19 | |
| N-Benzylaniline SCHEMBL3602124 | 0.92 | HTT (0.68) | CYP1A2MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19018313 | 0.91 | HTT (0.61) | CYP1A2MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9798992 | 0.91 | FFAR1 (0.68) | CYP1A2MEN1CYP3A4CYP2C9CYP2C19 | |
| N-Benzylaniline SCHEMBL10963734 | 0.90 | HTT (0.65) | CYP1A2MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1924100 | 0.89 | HTT (0.78) | CYP1A2MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1624682 | 0.89 | HTT (0.84) | CYP1A2MEN1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023171690-A1 | WEAK-ANCHORING LIQUID CRYSTAL ALIGNING AGENT AND LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023157879-A1 | WEAK-ANCHORING LIQUID CRYSTAL ALIGNING AGENT, AND LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2023-08-24 | — | — | WO | disclosed |
| WO-2023120726-A1 | WEAK-ANCHORING LIQUID CRYSTAL ALIGNMENT AGENT, AND LIQUID CYRSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2023-06-29 | — | — | WO | disclosed |
| US-11622916-B2 | Photocurable composition excellent in curing depth | SHOFU INC. (JP) | 2023-04-11 | — | — | US | disclosed |
| WO-2023048278-A1 | WEAKLY ANCHORING LIQUID-CRYSTAL ALIGNMENT AGENT, LIQUID-CRYSTAL DISPLAY ELEMENT, AND POLYMER | 日産化学株式会社 | 2023-03-30 | — | — | WO | disclosed |
| WO-2022260048-A1 | WEAK ANCHORING LIQUID CRYSTAL ALIGNING AGENT, LIQUID CYRSTAL DISPLAY ELEMENT AND COPOLYMER | 日産化学株式会社 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022196565-A1 | LIQUID-CRYSTAL COMPOSITION, LIQUID-CRYSTAL DISPLAY ELEMENT PRODUCTION METHOD, AND LIQUID-CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2022-09-22 | — | — | WO | disclosed |
| US-20220287919-A1 | PHOTOCURABLE COMPOSITION EXCELLENT IN CURING DEPTH | SHOFU INC. (JP) | 2022-09-15 | — | — | US | disclosed |
| US-8008312-B2 | CXCR4 antagonists for the treatment of HIV infection | EMORY UNIVERSITY (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008312-B2 | CXCR4 antagonists for the treatment of HIV infection | EMORY UNIVERSITY (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100006495-A1 | SEMIPERMEABLE POLYMERS AND METHOD FOR PRODUCING SAME | ELTRON RESEARCH AND DEVELOPMENT, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100006495-A1 | SEMIPERMEABLE POLYMERS AND METHOD FOR PRODUCING SAME | ELTRON RESEARCH AND DEVELOPMENT, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090099194-A1 | CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders | EMORY UNIVERSITY | 2009-04-16 | — | — | US | disclosed |
| US-20090099194-A1 | CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders | EMORY UNIVERSITY | 2009-04-16 | — | — | US | disclosed |
| WO-2008008854-A9 | CXCR4 ANTAGONISTS INCLUDING DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL DISORDERS | UNIV EMORY (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008008854-A2 | CXCR4 ANTAGONISTS INCLUDING DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11622916-B2 | Photocurable composition excellent in curing depth | ODC1, AOC2, CCNT1 | CYP1A2 856/4885MEN1 3523/4885CYP3A4 2742/4885 |
| US-20220287919-A1 | PHOTOCURABLE COMPOSITION EXCELLENT IN CURING DEPTH | ODC1, AOC2, CCNT1 | CYP1A2 862/4885MEN1 3562/4885CYP3A4 2731/4885 |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | CXCR4, CXCL12, CXCR1 | CYP1A2 4753/4885MEN1 2244/4885CYP3A4 4824/4885 |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | CYP1A2 1737/4885MEN1 500/4885CYP3A4 1391/4885 |
| US-20090099194-A1 | CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders | CXCR4, CXCL12, CCR5 | CYP1A2 4268/4885MEN1 1744/4885CYP3A4 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.